In the context of the health crisis we are currently experiencing and since the transition to level 3 vigilance, all the measures have been implemented by Europhartech to protect its employees and guarantee the continuation of business for its customers. To date, our production staff, i.e. 80% of our employees, are present, which enables us to maintain our usual level of activity. All precautions are taken to guarantee adequate working conditions for our employees in order to meet our business continuity plan. All employees who are able to work remotely have been placed on teleworking. These new protective measures and their implementation could cause some delay in certain procedures and we thank you for your understanding. The ANSM has asked us to maintain the activity by prioritizing the production of human drugs and the Drugs of Major Therapeutic Interest are given priority. This information applies at this time, pending future government decisions or announcements and subject to the uninterrupted component supply chain.